Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis

Nicole Rizkalla, Chris Feudtner, Dingwei Dai, Athena F. Zuppa

Research output: Contribution to journalArticle

Abstract

Objectives: Care for the pediatric patient with acute renal failure who requires hemodialysis (including continuous renal replacement therapy) is made more complex, as this intervention may significantly affect drug clearance, potentially altering, to a degree that is largely unknown, the effectiveness and safety of the multiple medications used to manage this complex patient population. This study aims to describe patterns of drug utilization among a large cohort of pediatric patients requiring hemodialysis and to document the easily accessible existing data available for dosing guidance of frequently prescribed medications. Study Design: Retrospective cohort using the Pediatric Health Information System database. Setting: Forty freestanding children's hospitals throughout the United States. Patients: Two thousand seven hundred thirty-eight pediatric patients with acute renal failure treated with hemodialysis from 2007 to 2011. Intervention: A retrospective review of all patients requiring hemo-dialysis from 2007 to 2011 was conduction using the Pediatric Health Information System Database. Main Results: Over 6% of pediatric patients with acute renal failure treated with hemodialysis were exposed to hemodialysis for over 2 weeks. Cumulative exposure to distinct drugs increased substantially with more prolonged courses of hemodialysis. Of the 50 most frequently prescribed medications in the cohort with acute renal failure treated with hemodialysis, 10% have readily available and easily accessible information to guide dosing adjustments with the use of hemodialysis. Furthermore, only 18% of these medications have clear recommendations for dosing in pediatric patients of all age groups with renal failure. Conclusions: Pediatric patients with acute renal failure managed with hemodialysis are exposed to a broad variety of medications, with a high prevalence of polypharmacy. There is a trend for longer courses of hemodialysis in these patients, which leads to an increase in cumulative drug exposure, complexity of drug interactions, and potential toxicity. For the vast majority of medications that are being used to treat this complex patient population, pediatric dosing guidance is not easily accessible. These findings underscore the need for targeted pharmacologic studies of medications used in the pediatric population managed with hemodialysis.

Original languageEnglish (US)
JournalPediatric Critical Care Medicine
Volume14
Issue number9
DOIs
StatePublished - 2013

Fingerprint

Acute Kidney Injury
Renal Dialysis
Pediatrics
Health Information Systems
Pharmaceutical Preparations
Databases
Population
Drug Utilization
Polypharmacy
Renal Replacement Therapy
Drug Interactions
Renal Insufficiency
Dialysis
Patient Care
Retrospective Studies
Age Groups
Safety

Keywords

  • Acute renal failure
  • Drug utilization
  • Hemodialysis
  • Pediatrics pharmacoepidemiology
  • Prescribing practices
  • Renal replacement therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Critical Care and Intensive Care Medicine

Cite this

Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis. / Rizkalla, Nicole; Feudtner, Chris; Dai, Dingwei; Zuppa, Athena F.

In: Pediatric Critical Care Medicine, Vol. 14, No. 9, 2013.

Research output: Contribution to journalArticle

@article{e3cf2ffd82114b4abc9ae330302ace80,
title = "Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis",
abstract = "Objectives: Care for the pediatric patient with acute renal failure who requires hemodialysis (including continuous renal replacement therapy) is made more complex, as this intervention may significantly affect drug clearance, potentially altering, to a degree that is largely unknown, the effectiveness and safety of the multiple medications used to manage this complex patient population. This study aims to describe patterns of drug utilization among a large cohort of pediatric patients requiring hemodialysis and to document the easily accessible existing data available for dosing guidance of frequently prescribed medications. Study Design: Retrospective cohort using the Pediatric Health Information System database. Setting: Forty freestanding children's hospitals throughout the United States. Patients: Two thousand seven hundred thirty-eight pediatric patients with acute renal failure treated with hemodialysis from 2007 to 2011. Intervention: A retrospective review of all patients requiring hemo-dialysis from 2007 to 2011 was conduction using the Pediatric Health Information System Database. Main Results: Over 6{\%} of pediatric patients with acute renal failure treated with hemodialysis were exposed to hemodialysis for over 2 weeks. Cumulative exposure to distinct drugs increased substantially with more prolonged courses of hemodialysis. Of the 50 most frequently prescribed medications in the cohort with acute renal failure treated with hemodialysis, 10{\%} have readily available and easily accessible information to guide dosing adjustments with the use of hemodialysis. Furthermore, only 18{\%} of these medications have clear recommendations for dosing in pediatric patients of all age groups with renal failure. Conclusions: Pediatric patients with acute renal failure managed with hemodialysis are exposed to a broad variety of medications, with a high prevalence of polypharmacy. There is a trend for longer courses of hemodialysis in these patients, which leads to an increase in cumulative drug exposure, complexity of drug interactions, and potential toxicity. For the vast majority of medications that are being used to treat this complex patient population, pediatric dosing guidance is not easily accessible. These findings underscore the need for targeted pharmacologic studies of medications used in the pediatric population managed with hemodialysis.",
keywords = "Acute renal failure, Drug utilization, Hemodialysis, Pediatrics pharmacoepidemiology, Prescribing practices, Renal replacement therapy",
author = "Nicole Rizkalla and Chris Feudtner and Dingwei Dai and Zuppa, {Athena F.}",
year = "2013",
doi = "10.1097/PCC.0b013e31829f5bc8",
language = "English (US)",
volume = "14",
journal = "Pediatric Critical Care Medicine",
issn = "1529-7535",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis

AU - Rizkalla, Nicole

AU - Feudtner, Chris

AU - Dai, Dingwei

AU - Zuppa, Athena F.

PY - 2013

Y1 - 2013

N2 - Objectives: Care for the pediatric patient with acute renal failure who requires hemodialysis (including continuous renal replacement therapy) is made more complex, as this intervention may significantly affect drug clearance, potentially altering, to a degree that is largely unknown, the effectiveness and safety of the multiple medications used to manage this complex patient population. This study aims to describe patterns of drug utilization among a large cohort of pediatric patients requiring hemodialysis and to document the easily accessible existing data available for dosing guidance of frequently prescribed medications. Study Design: Retrospective cohort using the Pediatric Health Information System database. Setting: Forty freestanding children's hospitals throughout the United States. Patients: Two thousand seven hundred thirty-eight pediatric patients with acute renal failure treated with hemodialysis from 2007 to 2011. Intervention: A retrospective review of all patients requiring hemo-dialysis from 2007 to 2011 was conduction using the Pediatric Health Information System Database. Main Results: Over 6% of pediatric patients with acute renal failure treated with hemodialysis were exposed to hemodialysis for over 2 weeks. Cumulative exposure to distinct drugs increased substantially with more prolonged courses of hemodialysis. Of the 50 most frequently prescribed medications in the cohort with acute renal failure treated with hemodialysis, 10% have readily available and easily accessible information to guide dosing adjustments with the use of hemodialysis. Furthermore, only 18% of these medications have clear recommendations for dosing in pediatric patients of all age groups with renal failure. Conclusions: Pediatric patients with acute renal failure managed with hemodialysis are exposed to a broad variety of medications, with a high prevalence of polypharmacy. There is a trend for longer courses of hemodialysis in these patients, which leads to an increase in cumulative drug exposure, complexity of drug interactions, and potential toxicity. For the vast majority of medications that are being used to treat this complex patient population, pediatric dosing guidance is not easily accessible. These findings underscore the need for targeted pharmacologic studies of medications used in the pediatric population managed with hemodialysis.

AB - Objectives: Care for the pediatric patient with acute renal failure who requires hemodialysis (including continuous renal replacement therapy) is made more complex, as this intervention may significantly affect drug clearance, potentially altering, to a degree that is largely unknown, the effectiveness and safety of the multiple medications used to manage this complex patient population. This study aims to describe patterns of drug utilization among a large cohort of pediatric patients requiring hemodialysis and to document the easily accessible existing data available for dosing guidance of frequently prescribed medications. Study Design: Retrospective cohort using the Pediatric Health Information System database. Setting: Forty freestanding children's hospitals throughout the United States. Patients: Two thousand seven hundred thirty-eight pediatric patients with acute renal failure treated with hemodialysis from 2007 to 2011. Intervention: A retrospective review of all patients requiring hemo-dialysis from 2007 to 2011 was conduction using the Pediatric Health Information System Database. Main Results: Over 6% of pediatric patients with acute renal failure treated with hemodialysis were exposed to hemodialysis for over 2 weeks. Cumulative exposure to distinct drugs increased substantially with more prolonged courses of hemodialysis. Of the 50 most frequently prescribed medications in the cohort with acute renal failure treated with hemodialysis, 10% have readily available and easily accessible information to guide dosing adjustments with the use of hemodialysis. Furthermore, only 18% of these medications have clear recommendations for dosing in pediatric patients of all age groups with renal failure. Conclusions: Pediatric patients with acute renal failure managed with hemodialysis are exposed to a broad variety of medications, with a high prevalence of polypharmacy. There is a trend for longer courses of hemodialysis in these patients, which leads to an increase in cumulative drug exposure, complexity of drug interactions, and potential toxicity. For the vast majority of medications that are being used to treat this complex patient population, pediatric dosing guidance is not easily accessible. These findings underscore the need for targeted pharmacologic studies of medications used in the pediatric population managed with hemodialysis.

KW - Acute renal failure

KW - Drug utilization

KW - Hemodialysis

KW - Pediatrics pharmacoepidemiology

KW - Prescribing practices

KW - Renal replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84892818676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892818676&partnerID=8YFLogxK

U2 - 10.1097/PCC.0b013e31829f5bc8

DO - 10.1097/PCC.0b013e31829f5bc8

M3 - Article

C2 - 23965636

AN - SCOPUS:84892818676

VL - 14

JO - Pediatric Critical Care Medicine

JF - Pediatric Critical Care Medicine

SN - 1529-7535

IS - 9

ER -